New Zealand Anemia Drugs Market Analysis

The New Zealand Anemia Drugs Market size stood at around xx Bn in 2023 and is projected to reach US $xx Bn by 2033, exhibiting a CAGR of xx% during the forecast period.

The New Zealand Anemia Drugs Market Analysis Executive Summary

Anemia refers to a situation in which the body has a low number of healthy red blood cells or haemoglobin to transport oxygen within the body tissues. Haemoglobin is a protein residing in red cells where it plays the role of transporting oxygen from the lungs to other parts of the body. Some of the effects of anemia include fatigue, weakness and possibly shortness of breath. Anemia has many types. They all have their reasons for being there. Anemia can be acute also known as the temporary kind or chronic which is the long-term kind. It can be as mild as a mere skin rash or flu and can be as severe as Ebola or even a heart attack. Also, anemia is often the first sign of a severe disease. Global research proves that anemia is prevalent in 40% of children aged between 6-59 months, 37 % of pregnant women, and 30 % of women, of reproductive age. Common therapies used in the treatment of anemia include iron tablets like ferrous sulphate, ferrous gluconate or iron polysaccharide, and intramuscular or intravenous iron like iron dextran. 

The anemia drugs market is evolving due to the rising incidence of anemia resulting from poor diet, diseases and old age. These are the market of iron supplements erythropoiesis stimulating agents and new therapies. There is also an increased growth in the regional markets such as North America, Europe and Asia-Pacific due to spending on healthcare in the emerging markets. However, factors like high costs of treatment, safety concerns, and poor availability of health infrastructure, particularly in the developing economies can hamper access and hence the markets. Future trends would also include technologies, governments and corporate fight against anemia, and a growing emphasis on business opportunities in new markets, which expands the market even further.    

New Zealand Anemia Drugs Market Dynamics

Market Growth Drivers

The global anemia market is expanding based on the increasing incidence, especially of IDA, connected to a poor-quality diet, chronic diseases, and restricted access to healthcare in developing countries. The rising elderly and women’s healthcare concerns due to pregnancy and menstruation are spurring anemia demands. Increased investment health and the progressing consciousness about it are resulting in early detection and managing of ailments, while advances in pharmaceutical composition and delivery systems are anew invigorating treatment choices. Such as, the government policies and higher spending on research & development by the pharmaceutical industries are also contributing to growth in the market, bringing down the barriers of accessibility and cost of higher usability along with further advancement in treatment remedies wanted. 

Opportunity

Trends in the anemia market that will be prominent in the future include increased efforts towards targeting the elderly and patients with chronic diseases given a rising incidence of anemia. Advancements in molecular biology and in the pharmaceutical industry promise improvement in therapeutic outcomes. The growth in to the untapped markets especially in Asia-Pacific along with diversification and extension of patents, advanced drug delivery systems and key alliances will help to fuel market growth and diversification. 

Market Restraints

The market of anemia has several issues that can affect its further development. Several factors such as high treatment cost especially in low end areas with scarce health facilities hinders patient access and therefore limits market potential. Such treatments as Blood transfusion, can in one way or the other, lessen the market for the anemia drugs. It is argued that fear of side effects, and cardiovascular risk particularly, can deter doctors, and patients, and influence the demand in the market. Lack of health education and facilities on global health in developing countries largely leads to under-diagnosis and under-treatment. Economic fluctuation may affect the expenditure for HE and the anemia treatments. These factors all combined are strong limitations to the market’s growth and advancement. 

Competitive Landscape Anemia Drugs Market in New Zealand

Key Players

• Sanofi
• AbbVie Inc. (Allergan Plc)
• Pharmacosmos A/S.
• Covis Pharma GmbH.
• Pfizer Inc. (Global Blood Therapeutics, Inc.)
• GlaxoSmithKline plc.

Recent Developments

March 2024, Cadila Pharmaceuticals announces the launch of novel iron injection, a next generation solution for addressing iron deficiency anemia.

March 2024, Akums launches sickle cell anaemia drug for 1% of global price.

March 2024, The FDA approved Akebia Therapeutics' (AKBA.O), opens new tab drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in dialysis patients

July 2023, GSK scraps plan to launch oral anemia drug in EU, ceases further expansion efforts.

Mergers and Acquisitions

February 2020, Fresenius Kabi and Vifor Pharma have formed a joint venture in China to provide patients access to vital blood management treatment. 

Healthcare Policies and Regulatory Landscape for Anemia Drugs Market in New Zealand

Policy changes and Reimbursement scenario

Historical government health care programs like the recently launched and consistent Indian campaign of AMB (Anaemia Mukt Bharat) will seek to contribute towards eradication of anaemia through targeted intervention and awareness drives and thus ensure there is enhanced demand for the drugs for anemia. More financial reinforcement from the government on research and development benefits the technological advancement and availability for treatment. However, the reimbursement scenario is different; developed countries provide better reimbursement for anemia treatments than the developing countries where high costs and a limited number of insurances hinder the development. The reimbursement environment may get better and demand will rise because of enhanced healthcare expenditure and personal income in emerging markets. Technological evolution and introduction of new therapies may have a positive impact in reimbursement issues thus contributing to the growth of the market.